It just doesn't appear that the writing on the wall is indicating that... Pfizer is putting a lot of emphasis on purchasing a company that will help them stay competitive and grow the bottom line, in this space. What Synta needs right now is some fantastic trial results. That will lure another company to collaborate with them in 2015... I was talking with someone this weekend that told me that Pfizer discontinued their research with Synta a few years ago because they were having too difficult of a time figuring out HsP90. Big pharma's will do this often. They have a criteria for which they continue their investment with an incubator company. For whatever their reasons were, they decided to stop working with Synta on developing this. Things may have changed and gotten better with Synta. I don't know. The insider purchasing isn't a bad signal but I don't see a clear cut case for being purchased or acquired.
Just another piece of info to think about, the discovery of Viagra was on accident. They were researching another disease and the males in the study group had an obvious side effect. Overnight erectile dysfunction had a name and a cure.